Emerging Pathogen Preparedness Program Authorization Act

S 2329 establishes a new FDA program to accelerate the development of medical tools (like vaccines and treatments) for emerging infectious diseases. The program will fund research on safety standards, maintain disease surveillance, ensure blood supply safety, and prioritize platform vaccine technologies for faster emergency use. It authorizes $60 million annually from 2024 to 2028 to support these activities through grants and contracts. The bill does not change the FDA’s existing authority to approve or authorize medical products under current law.